Authors
Latest:
Next-Gen BCL-2 Inhibitor Shows Deep Responses in MyelomaA new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early responses in heavily pretreated patients with relapsed/refractory multiple myeloma harboring t(11:14).
Latest:
Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene AmplificationsSenthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain MetsNancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.
Latest:
Biomarker Analysis Predicts Post-Osimertinib Response in EGFR+ NSCLCBenjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
Triple Therapy Demonstrates Early Activity in Refractory MyelomaA novel, all-oral combination regimen of mezigdomide, tazemetostat, and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma.
Latest:
Increased Rates of Viral Infections in Multiple MyelomaHeinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Latest:
Spiegel Discusses the Phase 2 Study Evaluating CRG-022 in R/R LBCLJay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.
Latest:
Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid CarcinomaChristine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Latest:
Comparing Tandem Stem Cell Transplant Approaches in Multiple MyelomaNicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Improving Upon Immunotherapy Advances in HCCBruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.
Latest:
Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma SpaceThomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Latest:
Colorectal Cancer Awareness Month: Overcoming Barriers to Early DetectionCharles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Latest:
I-SPY2.2: A Personalized Medicine Trial for Neoadjuvant Breast Cancer TreatmentRebecca Shatsky, MD, discusses findings from the ISPY2.2 trial presented at the 2024 ASCO Annual Meeting.
Latest:
Artificial Intelligence and Machine Learning in Cancer DetectionArtificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Latest:
BTK Inhibitor Therapy Can Be Stopped in CLLThe decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
Latest:
Daratumumab Regimen May Be the More Active Therapy Needed for AmyloidosisEfstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Latest:
Confronting Challenges and Embracing Progress in HER2+ Breast CancerYara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.
Latest:
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung CancerResearch shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Latest:
Company-wide Initiative Will Provide Standards for Collection and StorageThe Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Latest:
The Promise of ALLO-501A in Relapsed/Refractory LBCLMichael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.
Latest:
Eric Cheung: Competence and Compassion are Key to Earning Patients' TrustEric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and his patient-centered approach to care.
Latest:
An Explosion of Agents for Myeloma TreatmentPrerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.
Latest:
Future Perspectives and Unmet Needs in the Treatment of Ovarian CancerChad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
Latest:
Olaparib Trial Supports 2-Year Treatment Duration in Ovarian CancerWilliam H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
